Becton, Dickinson and Company (NYSE:BDX) Holdings Raised by Graybill Wealth Management LTD.

Graybill Wealth Management LTD. boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 0.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,530 shares of the medical instruments supplier’s stock after buying an additional 139 shares during the period. Graybill Wealth Management LTD.’s holdings in Becton, Dickinson and Company were worth $4,227,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BDX. Livelsberger Financial Advisory acquired a new position in shares of Becton, Dickinson and Company during the third quarter valued at approximately $26,000. Sound Income Strategies LLC increased its position in shares of Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the period. Opal Wealth Advisors LLC acquired a new position in shares of Becton, Dickinson and Company during the 2nd quarter valued at $45,000. Abound Wealth Management lifted its holdings in shares of Becton, Dickinson and Company by 96.0% in the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after buying an additional 96 shares during the period. Finally, Tributary Capital Management LLC bought a new position in Becton, Dickinson and Company during the first quarter valued at about $49,000. 86.97% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Raymond James dropped their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their target price for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Evercore ISI lifted their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, Stifel Nicolaus lifted their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Stock Down 0.4 %

Shares of BDX traded down $0.90 during mid-day trading on Tuesday, reaching $239.62. The company’s stock had a trading volume of 123,122 shares, compared to its average volume of 1,384,083. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $262.23. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. The company has a market cap of $69.25 billion, a price-to-earnings ratio of 52.96, a price-to-earnings-growth ratio of 1.79 and a beta of 0.42. The business has a fifty day moving average of $237.14 and a 200 day moving average of $235.16.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. The firm had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period last year, the company posted $2.96 EPS. As a group, analysts forecast that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.